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Abstract: Natalizumab is a monoclonal antibody, representing a new class of medication 
for treating relapsing multiple sclerosis (MS). Conventional treatments include interferons, 
glatiramer acetate and chemotherapies such as mitoxantrone and cyclophosphamide. These 
therapies offer only modest clinical benefits and are commonly not tolerated due to side effects. 
Natalizumab has been proven in large-scale, blinded, randomized, controlled trials to have 
an exceptional effect on preventing relapses, decreasing the risk of sustained progression of 
disability, and increasing the rate of disease-free patients over a 24-month period compared 
to placebo. These trials led to the speedy approval of natalizumab for treating relapsing MS, 
but its use was halted a few months after its induction after several cases of progressive 
multifocal leukoencephalopathy (PML), a fatal demyelinating disease affecting the central 
nervous system. After a long deliberation by an FDA advisory panel and strong support from 
the MS community, natalizumab was reapproved with stringent restrictions including patient, 
provider and site registration. Natalizumab is now considered second-line therapy for patients 
who have failed first-line agents such as interferon or glatiramer acetate. As little is known 
about additional risk factors for PML and other potential infections, patients and providers 
must work together to carefully decide if potential benefits outweigh these rare but potentially 
devastating complications.
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Introduction
Multiple sclerosis (MS) is a chronic, progressive, irreversible, inflammatory disease 
involving the central nervous system, typically affecting white matter in the brain 
as well as the spinal cord. It is believed that MS is an autoimmune disease in which 
auto-reactive T-cells migrate across the blood–brain barrier and mediate an immune 
response against the central neurons. Specifically, the myelin sheath that covers the 
nerve’s axon and acts as an insulator is directly affected leading to demyelination of 
the nerve cell. Recent data suggest that direct axonal damage also occurs. This destruc-
tion of myelin and central neurons leads to conduction abnormalities, which can affect 
many different areas of the body. Patients suffering from MS may experience a variety 
of symptoms including fatigue, changes in sensation, locomotion, and cognition, loss 
of bladder or bowel control and many other troublesome effects. The diagnosis and 
monitoring of patients relies on excluding other causes and is largely based on clinical 
examination.1 However, cranial and spinal magnetic resonance imaging (MRI) scans 
provide practitioners with objective evidence, as lesions are often observed. Several 
subtypes of MS have been defined; however, most patients are initially diagnosed with Therapeutics and Clinical Risk Management 2009:5 586
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relapsing-remitting MS. This type is characterized by varying 
lengths of symptom-free periods interrupted by relapses, or 
attacks, marking new disease activity. A relapse is defined 
as a worsening of symptoms, peaking within 24 to 48 hours 
that usually lasts several weeks and may or may not resolve 
completely. Objectively, during an acute episode, lesions 
may be observed on T1-weighted MRI images after gado-
linium dye administration, which represent inflammation 
and acutely active demyelination. Performing a T1-weighted 
MRI with contrast is the standard when searching for new or 
newly active lesions in MS. Detecting and monitoring chronic 
damage is also performed using MRI scans. Lesions observed 
when performing T2-weighted MRI scans usually represent 
chronic and generally irreversible demyelination.
The therapeutic goals of treating MS are to reduce the 
frequency, severity and duration of relapses, to slow the pro-
gression of disability and to prevent sub-clinical activity and 
progression on MRI. It is thought that decreasing the number 
of acute, inflammatory relapses may lead to less long-term 
neurodegeneration and disability. Conventional treatments 
include interferons, glatiramer acetate and chemotherapies 
such as mitoxantrone and cyclophosphamide, among others. 
These therapies offer only modest benefits and are commonly 
not tolerated due to side effects such as flu-like symptoms, 
injection site reactions, depression, thyroid abnormalities, 
hepatic enzyme abnormalities, infections or even left ven-
tricular dysfunction and hemorrhagic cystitis in the cases 
of mitoxantrone and cyclophosphamide, respectively.2 The 
search for safer and more effective options continues, with 
investigations examining alternate targets and developing 
medications with unique mechanisms of action.
Natalizumab (Tysabri®; Biogen Idec, Cambridge, MA, 
USA) is a monoclonal antibody, representing a new class of 
medication for treating MS. Natalizumab also has an Food 
and Drug Administration (FDA)-approved indication for 
treating moderately to severely active Crohn’s disease in 
patients who are nonresponsive or are unable to tolerate con-
ventional therapies, but this paper will review the available 
efficacy and safety data on natalizumab for treating MS.
What is natalizumab?
Natalizumab is a recombinant humanized IgG4κ monoclonal 
antibody produced in murine myeloma cells. Specific proteins, 
called integrins, exist on the surface of all leukocytes, except 
neutrophils. Integrin binding to a counter-receptor located 
on endothelium is required for the passage of leukocytes 
across the endothelium, into inflamed parenchymal tissue. 
Natalizumab binds to the α4-subunit of α4β1 and α4β7 
integrins on the surface of leukocytes and inhibits their 
adhesion to endothelial receptors, specifically vascular cell 
adhesion molecule-1 on activated vascular endothelium and 
mucosal addressin cell adhesion molecule-1 present on vas-
cular endothelial cells of the gastrointestinal tract. Without 
this binding, leukocytes are unable to transmigrate across 
endothelium into inflamed parenchymal tissue. It is believed 
that in MS, by inhibiting this transmigration of specifically, 
T-lymphocytes into the brain, the autoimmune attack and 
subsequent inflammatory response to the central neurons is 
greatly reduced.3
Natalizumab is available as a 20 mg/mL solution that 
must be diluted before administration. The standard dose 
is 300 mg (one 15 mL vial), diluted in 100 mL of 0.9% 
sodium chloride and infused intravenously over one hour 
every 4 weeks.3
Efficacy data
Natalizumab has been studied in two large, randomized 
controlled trials. Polman et al randomized 942 patients with 
relapsing remitting MS to natalizumab 300 mg or placebo 
iv every 4 weeks in a 2:1 ratio for up to 116 weeks in the 
AFFIRM trial.4 The AFFIRM trial took place in 99 clinical 
centers throughout Europe, North America, Australia, and 
New Zealand beginning on November 6, 2001. The pri-
mary outcomes were rate of clinical relapse at 1 year and 
the cumulative probability of sustained progression of dis-
ability at 2 years. The cumulative probability of sustained 
progression of disability was measured using the Expanded 
Disability Status Scale (EDSS). The EDSS is a rating system 
that is frequently used for classifying and monitoring the 
extent of disability in patients with MS.5 The scale ranges 
from 0, which is a normal neurological examination, to 10, 
which is death from MS. The investigators defined sustained 
progression of disability as an increase of 1 or more on the 
EDSS from a baseline score of 1 or more or an increase of 
1.5 or more from a baseline score of 0 that was sustained 
for 12 weeks. Secondary outcomes were the presence of 
sub-clinical MRI data indicative of active disease or disease 
progression at the end of the 1- and 2-year time periods. 
Baseline characteristics were similar between the two groups 
with 70% of the patients being female. The mean age of the 
whole group was 36 years with mean disease duration of 
5 years. The patients had relatively active disease; averaging 
1.52 relapses within the previous year, but had minimal dis-
ability with a mean EDSS score of 2.3.
The results of the AFFIRM trial demonstrated a 
large benefit for patients taking natalizumab. At 2 years, Therapeutics and Clinical Risk Management 2009:5 587
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the cumulative probability of progression was 17% for 
natalizumab and 29% for placebo (P  0.001). This rep-
resents a 42% relative decrease in the risk of sustained 
progression of disability for patients taking natalizumab 
for 2 years. The effect on relapse rate at 1 year was also 
significant. The mean annualized relapse rate was reduced 
from 1.53 to 0.26 relapses per year in the natalizumab 
group compared to a reduction from 1.5 to 0.81 relapses per 
year in the placebo group. This represents a 68% relative 
reduction in annualized relapse rate for natalizumab, which 
was maintained throughout the second year of follow-up 
(P  0.001).
For the secondary, sub-clinical outcomes, natalizumab 
also showed good effects. The mean number of new or 
enlarging hyperintense lesions detected on T2-weighted 
MRI, was reduced by 83% in natalizumab treated patients 
compared to placebo (P  0.001). Furthermore, evidence 
of acutely active disease, represented by the appearance 
of gadolinium-enhancing lesions on T1-weighted MRI, 
was reduced by 92% for natalizumab patients compared to 
placebo (P  0.001).
The SENTINEL trial was the second study examining 
natalizumab, but did so as combination therapy.6 This trial 
randomized 1171 patients with relapsing remitting MS to 
natalizumab 300 mg or placebo iv every 4 weeks in a 1:1 
ratio in addition to interferon β-1a (Avonex, Biogen Idec) 
30 µg intramuscularly once weekly for up to 116 weeks. The 
SENTINEL trial took place in 124 clinical centers throughout 
Europe and the United States beginning on January 14, 2002. 
The primary outcomes were the same as those used in the 
AFFIRM trial; the rate of clinical relapse at 1 year and the 
cumulative probability of sustained progression of disability 
at 2 years. Secondary outcomes were also similar, including 
various sub-clinical MRI outcomes.
The combination of natalizumab with interferon β-1a 
proved to be considerably more effective than interferon 
β-1a alone. The risk of disability progression over a 
2-year period was reduced by 24% with combination 
therapy compared to interferon β-1a alone (P = 0.02). This 
effect was not as large as that reported in the AFFIRM trial, 
which is expected since all patients in the SENTINEL trial 
were receiving some therapy, but this benefit is substantial 
nonetheless. The annualized relapse rate was reduced by 54% 
with natalizumab plus interferon β-1a compared to interferon 
β-1a alone for the first year, which was maintained through-
out the second year of follow-up (P  0.001).
The addition of natalizumab to interferon β-1a also had 
dramatic effects on the predefined MRI outcomes, which 
were comparable to the AFFIRM trial. The effect on new 
or enlarging hyperintense lesions was exactly the same 
as was seen in the AFFIRM study with an 83% reduction 
observed with combination therapy compared to interferon 
β-1a alone (P  0.001). The appearance of gadolinium-
enhancing lesions on T1-weighted MRI was reduced by 89% 
for combination therapy compared to interferon β-1a alone 
(P  0.001).
A closer look at data from the AFFIRM trial presented 
at the World Congress on Treatment and Research in 
Multiple Sclerosis in Montreal in 2008 continued to show 
positive results of treatment with natalizumab.7 Investigators 
were interested in determining how many of the patients who 
received natalizumab were disease free over the 24 month 
period compared to placebo. After 2 years of therapy, the 
proportion of patients who were free of MRI lesion activity, 
defined as no gadolinium-enhancing lesions and no new or 
enlarging T2-hyperintense lesions, was 57.7% for natali-
zumab versus 14.2% for placebo (P  0.0001). Furthermore, 
the proportion of patients who were free of MRI lesion activ-
ity and free of clinical activity, defined as no new lesions 
on MRI as defined above and no relapse or progression of 
disability was 36.7% for natalizumab versus 7.2% for placebo 
(P  0.0001). These data are encouraging since the baseline 
level of disease activity was relatively high with 90% of 
the patients having experienced one to two relapses during 
the year prior to randomization.
Though the clinical efficacy of natalizumab was clearly 
demonstrated in the AFFIRM and SENTINEL trials, 
unfortunately, the SENTINEL trial was stopped approxi-
mately one month early on February 28, 2005, because of 
two reports of progressive multifocal leukoencephalopathy 
and natalizumab was voluntarily, but temporarily, withdrawn 
from the market by the manufacturer.
Progressive multifocal 
leukoencephalopathy (PML)
PML is a fatal demyelinating disease affecting the central 
nervous system of individuals who are immunosuppressed.8 
It is caused by the reactivation of the JC virus, a polyomavirus 
against which approximately 80% of the adult population 
has antibodies.9 As an opportunistic infection, it is com-
monly observed in patients with acquired immunodeficiency 
syndrome at a rate of about 4%.10 Other risk factors include 
lympho- and myeloproliferative disorders, solid tumors, con-
genital immunodeficiency disorders, and the use of chronic 
corticosteroids and chemotherapy.11 Though corticosteroids 
and chemotherapy are commonly used to treat MS, PML had Therapeutics and Clinical Risk Management 2009:5 588
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not been observed among the MS population prior to the use 
of natalizumab.
Presenting symptoms vary widely, but the most com-
monly observed are limb weakness, cognitive deficits, speech 
and visual deficits, incoordination, seizures, and paralysis.12 
Unfortunately, other than reconstitution of the immune 
system, there is currently no effective treatment for PML, 
and the mortality rate remains as high as 50%.8
The first patient to develop PML in the SENTINEL trial 
was a 46-year-old female who had received 37 doses of 
natalizumab beginning in April 2002 through January 2005 
as add on therapy to interferon β-1a.13 In November 2004 she 
reported new problems with hand-eye coordination and prob-
lems with her speech. She was treated with corticosteroids 
but her condition worsened, as she developed right-sided 
hemiparesis and worsening nonfluent aphasia. She eventually 
became nonresponsive and further work-up for various viral, 
bacterial and fungal etiologies was negative. At this time, 
the treating neurologist suspected PML and a cerebrospinal 
fluid (CSF) sample was sent out for JC virus PCR testing, 
which returned positive. The patient subsequently died on 
February 24, 2005.
The second patient was a 45-year-old male who had 
received 28 doses of natalizumab from October 2002 through 
December 2004 as add on therapy to interferon β-1a.14 During 
a routine study visit in November 2004, the patient’s physi-
cian observed uncharacteristic, inappropriate behavior. The 
patient subsequently reported to family members that he was 
having difficulty with attention and concentration. Over the 
following weeks, cognitive impairment developed along 
with mild left-sided hemiparesis and dysarthria. In February 
2005, serum samples sent for JC virus PCR testing returned 
positive, as did in situ hybridization testing from brain 
biopsy samples. Despite receiving a course of intravenous 
cidofovir and a course of intravenous immune globulin, 
his condition continued to worsen, now with left-sided 
hemiplegia, anesthesia and neglect accompanied by right-
sided hemiparesis and apraxia, nonfluent aphasia, severe 
cognitive impairment, and delirium. Intravenous cytarabine 
was initiated in early April, which caused pancytopenia that 
was treated successfully. Two weeks later, the patient started 
to improve. A second course of cytarabine was administered 
4 weeks after the first course and by the end of May, the 
patient was starting to be able to walk and talk, but was left 
with disabling ataxia, cognitive impairment, mild neglect, 
and mild left hemiparesis.
Though the administration of cytarabine to this particular 
patient was followed by dramatic improvement, this is an area 
that requires further research as one randomized, controlled 
trial failed to prove that this agent was effective in treating 
HIV-infected patients with PML.15 As the authors of this 
case report point out, if the beneficial outcome seen in their 
patient was attributable to the administration of cytarabine, 
this may be due to the significant break-down of this patient’s 
blood–brain barrier, as was seen on MRI, allowing the drug 
to better penetrate into the CNS. This permeability of the 
blood-brain barrier was a characteristic not shared by the 
patients treated in the HIV-infected study.
One must also note that reconstitution of the immune 
system is considered the only truly effective treatment for 
PML, which in HIV-infected individuals consists of admin-
istering highly active antiretroviral therapy.8 In cases involv-
ing natalizumab induced PML, this may require allowing 
significant time for the biological effects of the drug to wear 
off, which has been shown to be approximately 3 months.16 
In the previously discussed case, the patient did experience a 
central nervous system inflammatory reaction 3 months after 
his last dose of natalizumab, which represents a reconstitu-
tion of the immune system and offers another reason for his 
overall improvement.
Around the same time that these cases were being 
reported, a third case of PML was diagnosed in a 60-year-old 
male receiving natalizumab in a clinical trial for treating 
Crohn’s disease.17 Shortly before beginning treatment with 
natalizumab, he received treatment with infliximab. After 
starting natalizumab treatment, he was concurrently receiving 
azathioprine for a short period of time. He died in December 
2003 after receiving a total of eight doses of natalizumab.
These case reports resulted in the withdrawal of 
natalizumab from the market in February 2005, which marked 
the beginning of a lengthy investigation by an FDA advisory 
panel constructed to weigh the risks against the benefits of 
using natalizumab. After 16 months and dozens of testimonies 
from patients18 requesting that natalizumab be allowed back 
on the market, in June 2006 the FDA approved the return of 
the drug, but not without restrictions.3 The first restriction 
is that natalizumab is only to be used as monotherapy, 
since the original cases of PML were only seen in those 
patients who were receiving combination therapy. Secondly, 
natalizumab is only to be used as second-line therapy when 
patients have failed first-line agents. And lastly, all patients 
receiving natalizumab have to be enrolled in a registry. The 
manufacturer developed the Tysabri® Outreach: Unified 
Commitment to Health (TOUCH™) Prescribing Program. The 
TOUCH™ Prescribing Program is a registry in which patients, 
prescribers, pharmacies and infusion sites are registered. Therapeutics and Clinical Risk Management 2009:5 589
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It was designed to promote informed benefit-risk decision 
making, identify patients who may not be candidates for 
natalizumab therapy (ie immunosuppressed patients), and to 
monitor for and track the incidence of PML with natalizumab 
therapy. Outside of North America, a similar registry exists 
called the Tysabri® Global Observational Program in Safety 
(TYGRIS).
Unfortunately, the story on PML with natalizumab 
therapy doesn’t end there. Since its return to the market 
in June of 2006, about 52,000 patients have received 
natalizumab world-wide. Since that time, there have 
been an additional 10 cases of PML reported in patients 
receiving natalizumab.19 According to an emailed letter 
from the manufacturer, (July 9, 2009) the six females 
and four males ranging from 27 to 59 years old, received 
natalizumab as monotherapy for 12 to 33 months. Nine 
of the patients had received prior treatment with other 
disease-modifying agents, including interferons, glatiramer 
acetate, mitoxantrone, intravenous immune globulin G, and 
azathioprine. One of the patients did not survive, while the 
others are left with varying degrees of neurological deficit 
ranging from being bedridden and requiring ventilatory 
support to slight hemiparesis and requiring ambulatory aids. 
These postmarketing cases have brought to light a couple 
of important concerns. Firstly, none of these patients were 
being treated with combination therapy. Therefore, practi-
tioners must now assume that PML is possible when treating 
patients with natalizumab as monotherapy. Secondly, and 
perhaps more importantly, one of the patients was treatment 
naïve. These factors now make it clear that anyone receiving 
natalizumab therapy may be at risk for developing PML, 
regardless of past or current therapies.
Although it is difficult to pinpoint the incidence of PML 
in natalizumab treated patients, it does appear that it is far 
less than the originally stated 1 per 1000 patients;20 current 
estimations are closer to 3 per 10,000 patients treated for 
2 years or more.19 Nonetheless, it is important to remember 
that this potentially fatal infection has not been observed in 
the MS population prior to the introduction of natalizumab. 
Cyclophosphamide drew great attention in the MS commu-
nity with the publication of a study reporting the stabilization 
of progressive MS patients after receiving high-dose cyclo-
phosphamide infusions in 1983.21 Similarly, mitoxantrone 
was shown to stabilize rapidly progressing MS patients in 
a study published in 1992.22 With over 25 years of experi-
ence with potent immunosuppressants, PML has never been 
observed in this population. Further research is imperative 
to establish a mechanism for natalizumab in causing PML 
and more importantly, to establish risk factors for identifying 
those at higher risk.
Optimistic data have emerged regarding possible treat-
ments for patients receiving natalizumab who develop PML. 
As previously mentioned, reconstitution of the immune sys-
tem appears to be the most promising approach to treating 
PML.8 Plasma exchange or immunoadsorption may offer 
some benefit for accelerating the clearance of natalizumab 
and thus restoring the function of leukocytes, which may 
prove vital for improving survival in natalizumab-induced 
PML cases. One such study enrolled 12 MS patients receiving 
natalizumab who underwent three plasma exchange sessions 
over 5 or 8 days after stopping natalizumab infusions. The 
investigators were able to reduce serum natalizumab concen-
trations in these patients by a mean of 92% after 1 week.23 
With few other options for treating these patients, these 
methods are often employed. All ten of the post-marketing 
patients who developed PML underwent either plasma 
exchange or immunoadsorption.
In addition, 5 of the patients were started on mefloquine. 
This antimalarial medication has been shown to inhibit JC 
virus replication in vitro.24 Furthermore, 2 of the patients 
were treated with mirtazapine. The serotonergic receptor, 
5-HT2a has been shown to be a cellular receptor for the JC 
virus on human glial cells. In vitro, 5-HT2a receptor antago-
nists inhibited JC virus infection.25 Mirtazapine is a 5-HT2a 
receptor antagonist that has been used to treat HIV-infected 
patients with PML.26 Data supporting the use of these agents 
are limited, but these therapies may be considered for treating 
natalizumab-induced PML.
Other infections
In clinical trials, natalizumab did not appear to increase 
the overall risk of infection when compared to placebo. 
Common infections, which were deemed mild to moderate, 
included nasopharyngitis, influenza, upper respiratory tract 
infections, urinary tract infections, and pharyngitis.4 Results 
were similar when natalizumab was added to interferon 
β-1a with the exception of pharyngitis. Seven percent of 
the patients treated with this combination developed phar-
yngitis compared to only 4% of the patients who received 
interferon β-1a alone (P  0.05).6 Of interest, one case of 
cryptosporidial gastroenteritis, an opportunistic infection, 
was reported in a patient receiving natalizumab.4 No other 
opportunistic infections were seen in clinical trials. However, 
at the FDA hearing for reapproval in 2006, several cases of 
opportunistic infections occurring in patients being treated for 
Crohn’s disease with natalizumab were presented, including Therapeutics and Clinical Risk Management 2009:5 590
Brown Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
a fatal case of Pneumocystis carinii pneumonia, one fatal 
case of pulmonary aspergillosis, a case of mycobacterium 
avium intracellulare complex pneumonia, and a case of 
Burkholderia cepacia pneumonia.27 Reactivation of herpes 
virus is also now a concern as one fatal case of herpes virus 
encephalitis and one nonfatal case of herpes virus meningitis 
have now been reported in patients receiving natalizumab.28 
In addition, data now exist showing that a larger percentage 
of patients receiving natalizumab have detectable varicella 
zoster virus DNA in their blood and saliva compared to 
subjects not receiving natalizumab. Furthermore, patients 
receiving natalizumab were three times more likely to have 
a herpes labialis eruption than untreated subjects.29 At this 
stage, these case reports are noteworthy but there is insuf-
ficient evidence to suggest a definitive relationship to treat-
ment with natalizumab. However, patients should continue 
to be closely monitored for any evidence of opportunistic 
infections and herpes reactivation. One question that may 
warrant further investigation is the use of the varicella zoster 
vaccine in patients scheduled to receive natalizumab. At this 
time, the vaccine is only indicated for individuals who are 
greater than 60 years old.30
Abnormal laboratory values
In clinical trials, the incidence of elevated hepatic enzymes 
was no different between natalizumab and placebo or 
control.4,6 However, in February 2008, the company updated 
the package insert to include hepatotoxicity as a warning 
for using natalizumab. After receiving several reports of 
clinically significant liver injury in patients having received 
natalizumab and evidence in some patients upon rechallenge, 
the company now recommends monitoring patients for 
elevations in hepatic transaminases and total bilirubin as 
well as advising patients to watch for signs and symptoms 
of liver injury.3
The only other notable abnormal lab values from clinical 
trials were increased plasma concentrations of lymphocytes, 
monocytes, eosinophils, and basophils.4,6 This is an expected 
observation, since the mechanism of action of the medication 
is the prevention of cellular transmigration across endothelial 
tissue, in essence sequestering these cells within the vascula-
ture. Notably, these effects are reversible, typically returning 
to baseline within 16 weeks after the last dose.
Immunogenicity
The development of neutralizing antibodies has long 
been a concern with MS therapies, ever since the first 
approved medication for treating MS, interferon β-1b, was 
approved in 1993.31 Though it is generally thought that the 
development of these antibodies renders interferons useless, 
15 years later there is still controversy surrounding how to 
interpret these findings. There is also debate on how to monitor 
for and manage patients who develop antibodies.32 This 
situation is not unlike that of natalizumab induced neutralizing 
antibodies. In the monotherapy treated patients, 9% of the 
patients receiving natalizumab developed neutralizing anti-
bodies at some time during the study. However, some patients 
only develop transient antibody production, which is thought 
not to affect the effectiveness of the medication. Overall, 
6% of the patients developed persistent antibodies, which 
was defined as detectable titers at least twice, separated by at 
least 42 days. Interestingly, these patients not only had loss of 
efficacy, but were more likely to experience infusion-related 
adverse events.4 Similar findings were observed when natali-
zumab was combined with interferon β-1a. Twelve percent 
of the patients receiving natalizumab and interferon β-1a 
developed antibodies at some time during the trial, whereas 
6% displayed persistent antibody production to natalizumab 
with similar clinical outcomes.6
In clinical practice, the utility of checking for neutraliz-
ing antibodies remains uncertain. If antibodies are present, 
this does not necessarily mean that the patient will remain 
producing antibodies and, therefore, they must be rechecked 
several weeks later. This could potentially delay a change 
in therapy that may be warranted if the second test reveals 
antibodies as well. Overall, it remains the case that it is best 
to treat patients clinically. However, one scenario in which 
antibodies should be measured is if a patient develops a 
reaction after receiving natalizumab, and the practitioner 
decides that treating through the reaction is an option. 
Treating through a reaction should not be done if a patient 
is producing neutralizing antibodies as this represents a true 
allergic type response to the medication.
Allergic reactions
Infusion reactions were defined as any event that occurred 
within two hours of the beginning of the infusion. In trials, 
24% of natalizumab infused patients experienced infu-
sion reactions compared to 18% of the placebo patients 
(P = 0.04). The most common reaction was headache, but 
also included dizziness, fatigue, urticaria, pruritus, and 
rigors. Most reactions were treated symptomatically and 
did not lead to discontinuation of the drug. Four percent 
of patients receiving natalizumab experienced hypersen-
sitivity reactions, whereas no patients receiving placebo 
did. A hypersensitivity reaction was deemed as such by Therapeutics and Clinical Risk Management 2009:5 591
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the investigator based on clinical judgment and severity. 
Hypersensitivity reactions were reported as urticaria, aller-
gic dermatitis, and anaphylactic or anaphylactoid reactions. 
Overall, eight of the reactions (1.3%) were considered 
serious reactions and five of them (0.8%) were considered 
anaphylactic or anaphylactoid reactions. All of the patients 
recovered without sequelae.3,4 Interestingly, there is no 
official recommendation by the company for premedicating 
patients before receiving natalizumab. As is recommended 
with other monoclonal antibodies,33,34 it makes sense that 
premedication may be considered for some patients at the 
prescriber’s discretion. The manufacturer does require 
patients to remain at the infusion site for 1 hour after the 
completion of their infusion for observation.3
Although most allergic reactions have been known to 
occur within two hours after the initiation of natalizumab 
infusions, it is now clear that delayed allergic reactions may 
occur as well. One such case involved a 23-year-old male 
patient with MS who presented to his physician 6 days after 
receiving his second dose of natalizumab, claiming eight 
hours after the infusion he collapsed and developed a fever 
of 39.4 °C, which he initially dismissed as a possible viral 
infection. Three days later he developed an itchy rash on his 
thighs and chest followed by a swollen lower lip 3 days after 
that. After ruling out other causes, the authors attributed this 
delayed reaction to natalizumab. The patient also tested posi-
tive for neutralizing antibodies to natalizumab that persisted 
for 8 weeks following discontinuation of the drug.35
It is clear that regardless of when the reaction occurs, the 
proper action to take if neutralizing antibodies are present is 
to discontinue natalizumab therapy. The decision becomes 
less clear when a patient has a reaction that could potentially 
be prevented or treated but without producing antibodies. One 
such paper describes two patients, in whom delayed systemic 
reactions occurred, consisting of arthralgias, headache, fever, 
neck stiffness, general malaise, tremor, and vertigo, begin-
ning several hours to days after the first infusion. Neither 
of the patients tested positive for neutralizing antibodies so 
they were continued on natalizumab therapy with subsequent 
infusions preceded by intravenous corticosteroids, histamine 
antagonists, and a reduced natalizumab infusion rate. In both 
cases the reactions diminished over time to a tolerable level 
and in one patient the reaction completely disappeared.36
A third case exists describing a very late allergic 
reaction that developed after 12 natalizumab infusions. This 
46-year-old male developed a mild arthralgia and headache 
2 days after his twelfth infusion that worsened over the course 
of the following week. A painful, erythematous, total body 
rash developed 8 days after the infusion, for which he was 
admitted to the hospital. Further work-up ruled out other 
causes, and although neutralizing antibodies to natalizumab 
were negative, he was deemed to have had a delayed allergic 
reaction to natalizumab. The patient went on to receive three 
more doses without premedication and without incident.37 
These cases may offer some guidance for treating patients 
who develop mild to moderate reactions to natalizumab 
without neutralizing antibody production.
Malignancy
In clinical trials, malignancy was rare with natalizumab 
therapy, occurring less than 1% of the time, which was not 
significant compared with placebo. Malignancies that were 
reported included breast cancer, cervical cancer, basal cell 
carcinoma and one fatal case of malignant melanoma.4,6 
Since its reapproval, there have been additional case reports 
of melanoma in patients receiving natalizumab. The first 
patient was a 46-year-old woman who only received one 
dose of natalizumab before she noticed a mole located on 
her shoulder that began to rapidly change. It was diagnosed 
as melanoma that had metastasized to regional lymph nodes. 
The second patient was a 45-year-old woman with a long-
standing history of an ocular nevus that developed into 
ocular melanoma after “several” (actual number of doses 
not reported) doses of natalizumab.38 Though these are only 
case reports, patients must be aware of this possibility and 
should be instructed to seek dermatologic evaluation should 
they have concerns about changes in skin lesions. It may also 
be prudent for patients to be examined by dermatology prior 
to initiating natalizumab therapy.
A third case report exists of a patient who developed 
primary central nervous system lymphoma (PCNSL).39 
PCNSL is a rare variant of extranodal non-Hodgkin 
lymphoma, primarily affecting patients in the seventh and 
eighth decades of life, for which immunosuppression is 
considered the major risk factor.40 This 40-year-old male 
patient received 21 doses of natalizumab as monotherapy 
for relapsing-remitting MS. Prior therapies included about 
8 months of high-dose interferon therapy, followed by about 
6 months of azathioprine therapy; neither of which were asso-
ciated with significant benefit. Following a four week wash 
out period, he was started on natalizumab. His response was 
less than optimal; however natalizumab was continued until 
an MRI scan revealed a new large gadolinium-enhancing 
lesion associated with mass effect and a midline shift. A brain 
biopsy, along with extensive diagnostic work-up to rule out 
extracerebral sources established the diagnoses of PCNSL. Therapeutics and Clinical Risk Management 2009:5 592
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The natalizumab therapy was discontinued and the patient 
underwent plasmapheresis, to accelerate the natalizumab 
clearance, followed by high-dose methotrexate therapy to 
treat the PCNSL.
MS is not known to be a risk factor for developing PCNSL. 
Since this patient was not significantly immunosuppressed, 
the association of natalizumab causing PCNSL can not be 
ruled. However, the authors also note that the potential role of 
azathioprine cannot be excluded either, as historically, there 
is a clear association between azathioprine and PCNSL.
Other adverse events
As monotherapy, other than allergic reactions, the only other 
adverse event that was reported more frequently and with 
statistical significance with natalizumab in comparison to 
placebo was fatigue. Twenty-seven percent of patients on 
natalizumab reported fatigue compared to 21% receiving 
placebo (P = 0.048).4 The actual clinical significance of 
this finding is unknown; however, it is feasible that this 
may inhibit some patients from tolerating the treatment. 
This finding was not seen when natalizumab was combined 
with interferon β-1a. However, anxiety, sinus congestion, 
and peripheral edema were seen more commonly in the 
combination group than in those who received interferon 
β-1a alone.6 Again, the clinical significance of these events 
is unclear, and in some respects, less relevant as combination 
is to be avoided regardless.
Is there a rebound phenomenon?
In the AFFIRM trial, a subgroup analysis of 51 patients did 
not show an excessive rebound effect when patients stopped 
medication. Although their disease activity returned to base-
line after discontinuation of natalizumab, their disease was 
no worse than patients receiving placebo.4 These data are 
challenged, however, by a smaller analysis of 21 patients 
from a single trial site, enrolled in either the AFFIRM or the 
SENTINEL trial.41 The suspension of natalizumab provided 
the opportunity for these investigators to assess rebound 
effects demonstrated by both clinical and MRI parameters. As 
a clinical outcome, no rebound effect was observed with the 
pretreatment annualized relapse rate being 1.15 and the post 
withdrawal annualized relapse rate being 0.73. However, on 
MRI, they found a significant increase in the development of 
new and enlarging T2-lesions in patients during the 15 months 
following natalizumab treatment compared to their lesion 
load during the 7 to 54 month pretreatment period; median 
annualized number of new and enlarging T2-lesions equals 
10.32 and 3.43, respectively (P = 0.014). Interestingly, this 
disparity was primarily driven by patients who had a short 
exposure to natalizumab, ranging from one to eight infu-
sions with a median of two infusions. Though these effects 
are marked, until these data are replicated in larger samples 
of patients, it is difficult to draw definitive conclusions. It is 
probable, however, that patients who receive at least 6 months 
of therapy are at less risk of excessive rebound effects should 
they have to discontinue therapy.
Another study found different results. The investigators 
enrolled 21 patients originally being treated in the AFFIRM 
or the SENTINEL trial, and followed them for 14 months 
after stopping natalizumab.42 To assess for the presence of 
any rebound effects, they monitored annual relapse rate, 
neurologic disease progression assessed by the EDSS, dis-
ease surrogate markers on MRI, and cellular and humoral 
immune markers in peripheral blood and CSF. Decreased 
lymphocyte cell numbers returned to normal after 14 weeks 
post-natalizumab, but they did not observe any clinical, 
radiographic, or immunologic rebound phenomenon. These 
patients received a median of 30 doses (range, 1 to 41).43 
These data support the hypothesis that patients who are 
treated for extended periods of time with natalizumab are 
unlikely to be at risk for a rebound phenomenon should they 
need to discontinue therapy.
Summary
Conventional therapies for treating MS offer modest efficacy 
and are not without considerable adverse effects. In this 
disabling disease, researchers struggle with developing 
novel agents aimed at halting its progressive nature, while 
maintaining an acceptable adverse event profile. Natalizumab 
has been proven in large-scale, blinded, randomized, 
controlled trials to have good effect on preventing relapses 
and decreasing the risk of sustained progression of 
disability in patients with relapsing MS. Furthermore, it 
has been shown to increase the rate of disease-free patients 
over a 24-month period compared to placebo. The rare 
occurrence of PML with natalizumab initially appeared to 
have devastating effects on the future of this medication. 
However, overwhelming support by the MS community 
along with a careful risk-benefit analysis won over the 
concerns of the FDA, allowing natalizumab to become 
reapproved for use as monotherapy in treating relapsing MS. 
Along with enrollment in the TOUCH Prescribing Program, 
natalizumab should only be considered for those patients 
with definite relapsing MS, patients who have not responded 
to or tolerated first line therapies, and patients who are not 
immunosuppressed nor have received immunosuppressive Therapeutics and Clinical Risk Management 2009:5 593
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therapies within the last 3 months. These requirements aim 
to reduce the risk of developing PML and to catch potential 
cases of PML as early as possible. Nonetheless, until more 
is known about additional risk factors, patients must be 
informed that individual susceptibility is not known and, 
therefore, clear risk assessment is difficult at this time. 
Likewise, with postmarketing case reports of serious herpes 
reactivation, early identification of such events is imperative. 
Continued analysis will clarify the true safety profile of 
natalizumab and better define its role in the treatment of 
multiple sclerosis.
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